Immune Checkpoint Inhibitors in Gliomas

Overview

Journal Curr Oncol Rep

Publisher Current Science

Specialty Oncology

Date 2017 Mar 18

PMID 28303490

Citations 26

Authors

Aaron C Tan

Amy B Heimberger

Mustafa Khasraw

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Malignant gliomas result in disproportionately high morbidity and mortality compared with other primary tumors, and progression of disease is inevitable. Novel therapies to improve outcomes are needed and immune checkpoint inhibitors hold significant promise.

Recent Findings: A limited body of preclinical evidence suggests that checkpoint inhibitors may be effective treatment for gliomas. Biomarkers to identify characteristics of gliomas responsive to these therapies will be essential. These may include mismatch repair deficiency and high mutational load that might be germline, somatic, or acquired after therapy. Evidence on the use of immune checkpoint inhibitors in gliomas is evolving. Clinical trials are underway and results are eagerly awaited. Understanding the role of immune checkpoint inhibitors in combination with other treatment modalities for gliomas is crucial to the improvement of outcomes. The design and conduct of future clinical trials need to account for increasingly complex treatment options.

Citing Articles

Overcoming immune evasion with innovative multi-target approaches for glioblastoma.

Su H, Peng Y, Wu Y, Zeng X Front Immunol. 2025; 16:1541467.

PMID: 39911397 PMC: 11794508. DOI: 10.3389/fimmu.2025.1541467.

Macrophage polarization-related gene signature for risk stratification and prognosis of survival in gliomas.

Zhong W, Xiong K, Li S, Li C J Cell Mol Med. 2024; 28(20):e70000.

PMID: 39448550 PMC: 11502305. DOI: 10.1111/jcmm.70000.

The Potential Significance of the EMILIN3 Gene in Augmenting the Aggressiveness of Low-Grade Gliomas is Noteworthy.

Wang L, Zheng Z, Zheng J, Zhang G, Wang Z Cancer Manag Res. 2024; 16:711-730.

PMID: 38952353 PMC: 11215280. DOI: 10.2147/CMAR.S463694.

Redox-responsive polymer micelles co-encapsulating immune checkpoint inhibitors and chemotherapeutic agents for glioblastoma therapy.

Zhang Z, Xu X, du J, Chen X, Xue Y, Zhang J Nat Commun. 2024; 15(1):1118.

PMID: 38320994 PMC: 10847518. DOI: 10.1038/s41467-024-44963-3.

Significance of NotchScore and JAG1 in predicting prognosis and immune response of low-grade glioma.

Shi B, Ge F, Cai L, Yang Y, Guo X, Wu R Front Immunol. 2023; 14:1247288.

PMID: 38022677 PMC: 10679421. DOI: 10.3389/fimmu.2023.1247288.

References

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-66. DOI: 10.1016/S1470-2045(09)70025-7. View

Sims J, Ung T, Neira J, Canoll P, Bruce J . Biomarkers for glioma immunotherapy: the next generation. J Neurooncol. 2015; 123(3):359-72. PMC: 4498992. DOI: 10.1007/s11060-015-1746-9. View

Sanmamed M, Chester C, Melero I, Kohrt H . Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies. Ann Oncol. 2016; 27(7):1190-8. DOI: 10.1093/annonc/mdw041. View

Reardon D, Okada H . Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials. J Neurooncol. 2015; 123(3):339-46. DOI: 10.1007/s11060-015-1748-7. View

Palma L, Di Lorenzo N, GUIDETTI B . Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases. J Neurosurg. 1978; 49(6):854-61. DOI: 10.3171/jns.1978.49.6.0854. View

Han S, Zhang C, Li Q, Dong J, Liu Y, Huang Y . Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma. Br J Cancer. 2014; 110(10):2560-8. PMC: 4021514. DOI: 10.1038/bjc.2014.162. View

Reardon D, Gokhale P, Klein S, Ligon K, Rodig S, Ramkissoon S . Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res. 2015; 4(2):124-35. DOI: 10.1158/2326-6066.CIR-15-0151. View

Chen T, Razak A, Bedard P, Siu L, Hansen A . A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol. 2015; 26(9):1824-1829. DOI: 10.1093/annonc/mdv182. View

10.

Agarwalla P, Barnard Z, Fecci P, Dranoff G, Curry Jr W . Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J Immunother. 2012; 35(5):385-9. PMC: 3352987. DOI: 10.1097/CJI.0b013e3182562d59. View

11.

Topalian S, Taube J, Anders R, Pardoll D . Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016; 16(5):275-87. PMC: 5381938. DOI: 10.1038/nrc.2016.36. View

12.

Johnson B, Mazor T, Hong C, Barnes M, Aihara K, McLean C . Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2013; 343(6167):189-193. PMC: 3998672. DOI: 10.1126/science.1239947. View

13.

Brahmer J, Drake C, Wollner I, Powderly J, Picus J, Sharfman W . Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010; 28(19):3167-75. PMC: 4834717. DOI: 10.1200/JCO.2009.26.7609. View

14.

Champiat S, Ferte C, Lebel-Binay S, Eggermont A, Soria J . Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy. Oncoimmunology. 2014; 3(1):e27817. PMC: 3937193. DOI: 10.4161/onci.27817. View

15.

Lee V, Murphy A, Le D, Diaz Jr L . Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade. Oncologist. 2016; 21(10):1200-1211. PMC: 5061538. DOI: 10.1634/theoncologist.2016-0046. View

16.

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

17.

Hodges T, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S . Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol. 2017; 19(8):1047-1057. PMC: 5570198. DOI: 10.1093/neuonc/nox026. View

18.

Postel-Vinay S, Aspeslagh S, Lanoy E, Robert C, Soria J, Marabelle A . Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. Ann Oncol. 2015; 27(2):214-24. DOI: 10.1093/annonc/mdv550. View

19.

Goldberg S, Gettinger S, Mahajan A, Chiang A, Herbst R, Sznol M . Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016; 17(7):976-983. PMC: 5526047. DOI: 10.1016/S1470-2045(16)30053-5. View

20.

Leung S, Chan T, Chung L, Chan A, Fan Y, Hung K . Microsatellite instability and mutation of DNA mismatch repair genes in gliomas. Am J Pathol. 1998; 153(4):1181-8. PMC: 1853047. DOI: 10.1016/S0002-9440(10)65662-3. View